Processa Pharmaceuticals, Inc. Amortization of Debt Issuance Costs
Processa Pharmaceuticals, Inc. (PCSA) reported Amortization of Debt Issuance Costs of $67.07 thousand for the 12-month period ending 2018-12-31, per its 10-K/A filed 2019-04-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2019-04-08
- Processa Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2018 was $67.07K, a 186.99% increase from fiscal 2017.
- Processa Pharmaceuticals, Inc. amortization of debt issuance costs for fiscal 2017 was $23.37K.
| Period end | Amortization of Debt Issuance Costs 12 month |
|---|---|
| 2018-12-31 | $67.07K 10-K/A · filed 2019-04-08 |
| 2017-12-31 | $23.37K 10-K/A · filed 2019-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |